scholarly journals Intracranial Angioplasty with Enterprise Stent for Intracranial Atherosclerotic Stenosis: A Single-Center Experience and a Systematic Review

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Bowen Sun ◽  
Chao Xu ◽  
Pei Wu ◽  
Man Li ◽  
Shancai Xu ◽  
...  
Keyword(s):  
Fixed Effects ◽  
High Rate ◽  
Arterial Stenosis ◽  
Single Center ◽  
Single Center Experience ◽  
Stent Restenosis ◽  
Intracranial Atherosclerotic Stenosis ◽  
Atherosclerotic Stenosis ◽  
Aggressive Medical Management ◽  
Medical University

Background. The high rate of periprocedural complications for the endovascular stent procedure in the Stenting Versus Aggressive Medical Management Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial resulted in it being less recommended than medical therapy to treat intracranial atherosclerotic stenosis (ICAS). Because Enterprise stent use might reduce the incidence of complications in ICAS treatment compared to other frequently used stents, this paper evaluated the safety and effectiveness of the Enterprise stent for the treatment of ICAS. Methods. We performed a comprehensive literature search for reports on intracranial angioplasty using the Enterprise stent for ICAS treatment from the earliest date available from each database to May 2020 for PubMed, EMBASE, Web of Science, Cochrane, and Clinical Trials databases. We also reviewed the single-center experience of the First Affiliated Hospital of Harbin Medical University. We extracted information regarding periprocedural complications, procedure-related morbidity, mortality, immediate angiographic outcome, and long-term clinical and angiographic outcomes, among others. Event rates were pooled across studies using random-effects or fixed-effects models depending on the heterogeneity. Results. Five hundred fifty-seven patients with 588 lesions from seven studies, including the institutional series, were included in the analysis. The incidence of stroke or death within 30 days was 7.4% (95% confidence interval (CI), 5.5%–10.1%). The incidence of ischemic stroke or TIA in the territory of the qualifying artery beyond 30 days and during follow-up was 3.2% (95% CI, 1.1%–9.5%). The incidence of in-stent restenosis was 10.1% (95% CI, 4.6%–22.2%), and the incidence of symptomatic restenosis was 4.1% (95% CI, 1.7%–9.9%). Conclusions. Intracranial angioplasty utilizing the Enterprise stent for ICAS treatment was relatively safe and effective but required further verification using additional sources for evidence.

Periprocedural risk and long-term outcome of intracranial angioplasty based on a single-centre experience

VASA ◽  
2013 ◽  
Vol 42 (4) ◽  
pp. 264-274
Author(s):  
Dagmar Krajíčková ◽  
Antonín Krajina ◽  
Miroslav Lojík ◽  
Martina Mulačová ◽  
Martin Vališ
Keyword(s):  
Death Rate ◽  
Long Term Outcomes ◽  
Single Centre ◽  
Intracranial Atherosclerotic Stenosis ◽  
Atherosclerotic Stenosis ◽  
Angioplasty And Stenting ◽  
Aggressive Medical Management ◽  
Stroke Death

Background: Intracranial atherosclerotic stenosis is a major cause of stroke and yet there are currently no proven effective treatments for it. The SAMMPRIS trial, comparing aggressive medical management alone with aggressive medical management combined with intracranial angioplasty and stenting, was prematurely halted when an unexpectedly high rate of periprocedural events was found in the endovascular arm. The goal of our study is to report the immediate and long-term outcomes of patients with ≥ 70 % symptomatic intracranial atherosclerotic stenosis treated with balloon angioplasty and stent placement in a single centre. Patients and methods: This is a retrospective review of 37 consecutive patients with 42 procedures of ballon angioplasty and stenting for intracranial atherosclerotic stenosis (≥ 70 % stenosis) treated between 1999 and 2012. Technical success (residual stenosis ≤ 50 %), periprocedural success (no vascular complications within 72 hours), and long-term outcomes are reported. Results: Technical and periprocedural success was achieved in 90.5 % of patients. The within 72 hours periprocedural stroke/death rate was 7.1 % (4.8 % intracranial haemorrhage), and the 30-day stroke/death rate was 9.5 %. Thirty patients (81 %) had clinical follow-up at ≥ 6 months. During follow-up, 5 patients developed 6 ischemic events; 5 of them (17 %) were ipsilateral. The restenosis rate was 27 %, and the retreatment rate was 12 %. Conclusions: Our outcomes of the balloon angioplasty/stent placement for intracranial atherosclerotic stenosis are better than those in the SAMMPRIS study and compare favourably with those in large registries and observational studies.

scholarly journals Carotid Artery Angioplasty and Stenting for Carotid Stenosis: A Single-Center Experience from Saudi Arabia

2020 ◽  
Vol 15 (3) ◽  
pp. 133-139
Author(s):  
Hussein Algahtani ◽  
Bader Shirah ◽  
Abdullah S. Alghamdi ◽  
Ahmad Subahi ◽  
Saeed A. Alqahtani ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Carotid Artery ◽  
Carotid Stenosis ◽  
Multidisciplinary Care ◽  
Healthcare Services ◽  
Single Center ◽  
Single Center Experience ◽  
Atherosclerotic Stenosis ◽  
Asymptomatic Patients ◽  
Medical City

Purpose: Atherosclerotic stenosis of the extracranial carotid artery accounts for approximately 20% of all strokes. Both carotid artery endarterectomy and carotid artery angioplasty with stenting (CAAS) are recommended for symptomatic patients with 50% or more stenosis or asymptomatic patients with 70% or more stenosis. CAAS is under-reported in Saudi Arabia, as evidenced by a thorough literature search. In this article, we aim to share our experience of CAAS to call for the necessity of conducting more research on stroke and emphasize the local need of utilizing more endovascular treatments like CAAS.Materials and Methods: A retrospective single-center observational study was conducted at King Abdulaziz Medical City in Jeddah, Saudi Arabia. The inclusion criteria consisted of all adult patients (18 years and above) with carotid stenosis who were treated with CAAS.Results: A total of 16 patients were included in the study. The mean age of the participants was 66.9±13.5 years (range 30–87 years). All patients were symptomatic (had a previous stroke or transient ischemic attack). The procedure was successful in 14 patients (87.5%), while it failed in 2 patients (12.5%) due to technical reasons. All patients had no stroke or myocardial infarction within 30 days of the procedure.Conclusion: Despite the advancement in medicine with free healthcare services in Saudi Arabia, the interventional procedures for secondary prevention of strokes are underutilized. Collaboration between different hospitals will be extremely helpful since few centers in each city are providing such treatments by an expert neurointerventionist and/or strokologist. The good selection of candidates, optimal management of comorbid conditions, and multidisciplinary care may improve outcomes and reduce mortality.

Single-Center Experience With Carotid Stent Restenosis

2002 ◽  
Vol 9 (3) ◽  
pp. 299-307 ◽  
Author(s):  
Andrea Willfort-Ehringer ◽  
Ramazanali Ahmadi ◽  
Michael E. Gschwandtner ◽  
Markus Haumer ◽  
Wilfried Lang ◽  
...  
Keyword(s):  
Carotid Stent ◽  
Single Center ◽  
Single Center Experience ◽  
Stent Restenosis

scholarly journals TCT-279 Comparison Of Two Paclitaxel-Coated Balloons In The Treatment Of Coronary In-Stent Restenosis: A Single Center Experience

2014 ◽  
Vol 64 (11) ◽  
pp. B81
Author(s):  
Javier Benezet ◽  
Santiago Camacho-Freire ◽  
Antonio Agarrado ◽  
Alejandro Gutierrez-Barrios ◽  
Jesus Oneto
Keyword(s):  
Single Center ◽  
Single Center Experience ◽  
Stent Restenosis ◽  
In Stent Restenosis

Abstract No. 139: Treatment of Renal Artery In-Stent Restenosis: Seven Year Single Center Experience

2008 ◽  
Vol 19 (2) ◽  
pp. S54 ◽  
Author(s):  
R.A. Lookstein ◽  
A. Fischman ◽  
J. Reinherz ◽  
R. Siegelbaum ◽  
J.L. Weintraub ◽  
...  
Keyword(s):  
Renal Artery ◽  
Single Center ◽  
Single Center Experience ◽  
Stent Restenosis ◽  
In Stent Restenosis
Sign in / Sign up

Export Citation Format

Share Document